A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission

Clinical and Experimental Rheumatology

Volumn 28, Issue 6, 2010, Pages 919-922

  Pratsidou Gertsi, P ^a   Trachana, M ^a   Pardalos, G ^a   Kanakoudi Tsakalidou, F ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Anti TNF; Etanercept; Juvenile arthritis disease activity score; Juvenile idiopathic arthritis; Outcome

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; ETANERCEPT; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; JUVENILE ARTHRITIS DISEASE ACTIVITY SCORE; JUVENILE RHEUMATOID ARTHRITIS; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REMISSION; SCHOOL CHILD; SCORING SYSTEM; TREATMENT DURATION; UVEITIS; DISABILITY; HOSPITALIZATION; PATHOPHYSIOLOGY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 79952676409     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Hayward K, Wallace CA: Recent developments on anti-rheumatic drugs in pediatrics: treatment of Juvenile Idiopathic Arthritis. Arthritis Res Ther 2009; 11: 216-27.
2. Ravelli A, Martini A: Juvenile idiopathic arthritis. Lancet 2007; 369: 767-78.
3. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A: Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
4. Ringold S.WALLACE CA: Measuring clinical response and remission in Juvenile Idiopathic Arthritis. Curr Opin Rheumatol 2007; 19:471-6.
5. Baraliakos X, Brandt J, Listing J et al:. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 2005; 53: 856-63.
6. Miyamura T, Sonomoto K, Nakamura M et al.: Discontinuation of etanercept in patients with rheumatoid arthritis who were in clinical remission. Clin Rheumatol 2010; 29: 87-90.
7. Prince FHM, Twilt MI SIMON SC: et al:. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2009; 68: 1228-9
8. Magni-Manzoni S, Ruperto N, Pistorio A et al:. Development and Validation of a Preliminary Definition of Minimal Disease Activity in patients with Juvenile Idiopathic Arthritis. Arthritis Rheum 2008; 59: 1120-7.
9. Consolaro A, Ruperto N, Bazsco A et al.: Development and validation of a Composite Disease Activity Score for Juvenile Idiopathic Arthritis. Arthritis Rheum 2009; 61:658-66.
10. Pian CE, McCann U: Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologies 2009; 3: 127-39.
11. Nielsen S, Ruperto N, Gerloni V et al.: Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008; 26: 688-92.